SynBioBeta Speaker
Jason Gammack
Ansa Biotechnologies
CEO
With over 25 years of experience in the life science and molecular diagnostic industry, I am a founder, investor, and advisor who helps innovative biotech companies achieve their full potential. I am currently the founder and managing director of JTG Investments & Advisory UG, a firm that provides strategic and financial guidance to emerging and established biotech companies in Europe and the US. Previously, I was the co-founder and CEO of Resolve BioSciences, a company that developed a revolutionary technology for spatial omics and single-cell analysis. I led the company from inception to acquisition, securing multiple rounds of funding, building a strong team, and launching the first product in the market. I also held senior executive roles at Inscripta, QIAGEN, Ingenuity Systems, and Affymetrix, where I drove the commercialization of disruptive life science tools and solutions, from concept to market ownership. I have a proven track record of increasing sales and growing the bottom line, while spearheading operational improvements and marketing strategies. I am passionate about bringing cutting-edge technologies and solutions to the life science research and clinical communities, and enabling them to advance scientific discovery and improve human health. I am an inspirational leader and dynamic storyteller who clearly articulates the vision and value proposition of the business, and empowers the team to achieve success. I excel in dynamic, demanding environments, while remaining pragmatic and focused. I am always looking for new opportunities and challenges to leverage my expertise and network, and to make a positive impact in the biotech sector.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Jason
This Year
•
-
Tools & Tech
Breaking the Barriers of DNA Synthesis: Shattering the Ceiling?
For decades, DNA synthesis has been the limiting reagent in synthetic biology — reliable for short sequences, but increasingly error-prone and costly as designs scale. That ceiling is now cracking. New enzymatic synthesis platforms, error-correction chemistries, and assembly pipelines are extending what’s possible, opening the door to rapid construction of full pathways, microbial genomes, and even mammalian chromosomes. This session will explore how innovators are breaking past barriers, what technical and economic breakthroughs are needed next, and how longer, cheaper, and faster synthesis could fundamentally change how we design biology at scale.
Get a Ticket
Featuring
Andrew Han
GenomeWeb
Editor
GenomeWeb editor covering sequencing and diagnostics markets.
Jason Gammack
Ansa Biotechnologies
CEO
Turning DNA synthesis into a predictable, on-time “reagent.”
Emily Leproust
Twist Bioscience
CEO
Leader in DNA Manufacturing, put DNA writing on silicon.
Monique Coy
Corteva Agriscience
Program Leader
Jodi Barrientos
Ribbon Bio
CEO
•
-
Tools & Tech
Breaking the Barriers of DNA Synthesis: Shattering the Ceiling?
For decades, DNA synthesis has been the limiting reagent in synthetic biology — reliable for short sequences, but increasingly error-prone and costly as designs scale. That ceiling is now cracking. New enzymatic synthesis platforms, error-correction chemistries, and assembly pipelines are extending what’s possible, opening the door to rapid construction of full pathways, microbial genomes, and even mammalian chromosomes. This session will explore how innovators are breaking past barriers, what technical and economic breakthroughs are needed next, and how longer, cheaper, and faster synthesis could fundamentally change how we design biology at scale.
Get a Ticket
Featuring
Andrew Han
GenomeWeb
Editor
GenomeWeb editor covering sequencing and diagnostics markets.
Jason Gammack
Ansa Biotechnologies
CEO
Turning DNA synthesis into a predictable, on-time “reagent.”
Emily Leproust
Twist Bioscience
CEO
Leader in DNA Manufacturing, put DNA writing on silicon.
Monique Coy
Corteva Agriscience
Program Leader
Jodi Barrientos
Ribbon Bio
CEO
•
-
Human Health
Spotlight Talk Brought to you By Ansa Biotechnologies
Get a Ticket
•
-
Human Health
Spotlight Talk Brought to you By Ansa Biotechnologies
Get a Ticket
•
-
AIxBIO
Programmable Molecules: AI and the Rise of Context-Aware Therapeutics
For the first time, AI is enabling us to imagine medicines that “think” - turning on only inside diseased cells or under specific physiological conditions. Neural networks trained on RNA, protein, and cellular data are unlocking a new generation of programmable therapies with unprecedented precision, from cancer drugs that remain inert until encountering tumor signals to RNA medicines capable of adapting to dynamic biological environments. But designing intelligent molecules is only part of the challenge. As AI expands the space of possible therapeutics, the field must also confront a critical question: how do we reliably build, test, and manufacture increasingly complex biological designs? This session explores the emerging continuum from AI-designed molecules to manufacturable programmable therapeutics, examining how advances in sequence design, synthesis, delivery, and validation are translating computational insight into real-world medicines. The future of medicine isn’t static molecules - it’s intelligent, adaptive therapeutics engineered across the full stack, from algorithm to clinic.
Get a Ticket
Featuring
Georgia Lu
Magnet Ventures
Founder & Mng Partner
AI-biotech investor blending M&A instincts with founder coaching.
Jason Gammack
Ansa Biotechnologies
CEO
Turning DNA synthesis into a predictable, on-time “reagent.”
Ashoka Madduri
Sanofi
Head, Scientific Strategy
AI-for-mRNA strategist shaping Sanofi’s genetic-medicine bets.
Simon Kohl
Latent Labs
Founder & CEO
Jacob Becraft
Strand
CEO & Co-founder
MIT “mRNA programming language” inventor building programmable RNA medicines. Former Ron Weiss lab, interned with Bob langer
•
-
AIxBIO
Programmable Molecules: AI and the Rise of Context-Aware Therapeutics
For the first time, AI is enabling us to imagine medicines that “think” - turning on only inside diseased cells or under specific physiological conditions. Neural networks trained on RNA, protein, and cellular data are unlocking a new generation of programmable therapies with unprecedented precision, from cancer drugs that remain inert until encountering tumor signals to RNA medicines capable of adapting to dynamic biological environments. But designing intelligent molecules is only part of the challenge. As AI expands the space of possible therapeutics, the field must also confront a critical question: how do we reliably build, test, and manufacture increasingly complex biological designs? This session explores the emerging continuum from AI-designed molecules to manufacturable programmable therapeutics, examining how advances in sequence design, synthesis, delivery, and validation are translating computational insight into real-world medicines. The future of medicine isn’t static molecules - it’s intelligent, adaptive therapeutics engineered across the full stack, from algorithm to clinic.
Get a Ticket
Featuring
Georgia Lu
Magnet Ventures
Founder & Mng Partner
AI-biotech investor blending M&A instincts with founder coaching.
Jason Gammack
Ansa Biotechnologies
CEO
Turning DNA synthesis into a predictable, on-time “reagent.”
Ashoka Madduri
Sanofi
Head, Scientific Strategy
AI-for-mRNA strategist shaping Sanofi’s genetic-medicine bets.
Simon Kohl
Latent Labs
Founder & CEO
Jacob Becraft
Strand
CEO & Co-founder
MIT “mRNA programming language” inventor building programmable RNA medicines. Former Ron Weiss lab, interned with Bob langer
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
